CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Article Stock Quotes (1)

FREE Breaking News Alerts from StreetInsider.com!

StreetInsider.com Top Tickers, 8/21/2026

1. WMT
2. ROST
3. AAP
4. SPY
5. NVDA

6. AVGO
7. BJ
8. OSIS
9. SFNC
10. FMG:AU

Get Alerts CRSP Hot Sheet

Price: $61.00 +4.96%

Overall Analyst Rating:
SELL (= Flat)

Join SI Premium – FREE

ZUG, Switzerland and CAMBRIDGE, Mass., April 01, 2019 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that members of its senior management team are scheduled to make the following presentations later this month:

Jefferies 6th Annual IO Cell Therapy Summit Date: Friday, April 5, 2019 Presentation: 4:05 p.m. ET Location: Boston, MA

Needham Annual Healthcare Conference Date: Tuesday, April 9, 2019 Presentation: 12:00 p.m. ET Location: New York, NY

A live webcast of the Needham event will be available on the "Events & Presentations" page in the Investors section of the Company's website at https://crisprtx.com/events. A replay of the webcast will be archived on the Company's website for 14 days following the presentation.

About CRISPR TherapeuticsCRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with leading companies including Bayer AG, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in London, United Kingdom. For more information, please visit www.crisprtx.com.

CRISPR Investor Contact:Susan Kim[email protected]

CRISPR Media Contact:Jennifer PaganelliWCG on behalf of CRISPR347-658-8290[email protected]